Rosiglitazone and cardiovascular risk [3]

New England Journal of Medicine

Volumn 357, Issue 9, 2007, Pages 938-

  Mannucci, Edoardo ^a   Monami, Matteo ^a   Marchionni, Niccolò ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RAMIPRIL; ROSIGLITAZONE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; FOLLOW UP; HEART INFARCTION; HUMAN; LETTER; MORBIDITY; PRIORITY JOURNAL;

EID: 34548358435     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105. [Erratum, Lancet 2006;368:1770.]
2. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43. [Erratum, N Engl J Med 2007;356:1387-8.]